Close Menu

NEW YORK (GenomeWeb) – Thermo Fisher Scientific said today that its board of directors has authorized the repurchase of $2 billion worth of shares of the firm's common stock, either in the open market or in negotiated transactions. The new authorization has no expiration date.

In July of 2016, the board had authorized the repurchase of $1.5 billion worth of shares, with $250 million remaining, which the company plans to deplete later this year.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

Public health experts call for a transparent COVID-19 vaccine approval process in a letter; the Food and Drug Administration commissioner assures science-based approval.

The Verge reports that new gene-naming guidelines aim in part to avoid Excel-related name change confusion.

In Nature this week: tuatara genome sequence aids in understanding amniote evolution, and more.

According to the Guardian, UK virologists say in a letter to officials that their expertise has been pushed aside in COVID-19 response plans.